Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis

Brain Research

Volumn 1390, Issue , 2011, Pages 126-141

  Lourbopoulos, Athanasios ^a   Grigoriadis, Nikolaos ^a   Lagoudaki, Roza ^a   Touloumi, Olga ^a   Polyzoidou, Eleni ^a   Mavromatis, Ioannis ^a   Tascos, Nikolaos ^a   Breuer, Aviva ^b   Ovadia, Haim ^c   Karussis, Dimitris ^c   Shohami, Ester ^d   Mechoulam, Raphael ^b   Simeonidou, Constantina ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

2 arachidonoylglycerol; Apoptosis; Axonopathy; CB1 receptor; CB2 receptor; encephalomyelitis; Endocannabinoid; Experimental autoimmune; Immunomodulation; M1 M2 microglia; Neuroprotection

Indexed keywords

2 ARACHIDONOYLGLYCEROL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; EX VIVO STUDY; FEMALE; IN VITRO STUDY; LYMPH NODE CELL; LYMPHOCYTE ACTIVATION; MACROPHAGE; MICROGLIA; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACUTE DISEASE; ANIMALS; ARACHIDONIC ACIDS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GLYCERIDES; MICE; MICE, INBRED C57BL; RANDOM ALLOCATION;

ANIMALIA; MUS;

EID: 79955610081     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2011.03.020     Document Type: Article

References (79)

1. Aldskogius, H., 2001. Microglia in neuroregeneration. Microsc. Res. Tech. 54, 40-46.
2. Arevalo-Martin, A., Garcia-Ovejero, D., Gomez, O., Rubio-Araiz, A., Navarro-Galve, B., Guaza, C., Molina-Holgado, E., Molina-Holgado, F., 2008. CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. Br. J. Pharmacol. 153, 216-225.
3. Arevalo-Martin, A., Garcia-Ovejero, D., Molina-Holgado, E., 2010. The endocannabinoid 2-arachidonoylglycerol reduces lesion expansion and white matter damage after spinal cord injury. Neurobiol. Dis. 38, 304-312.
4. Baker, D., Pryce, G., Croxford, J.L., Brown, P., Pertwee, R.G., Makriyannis, A., Khanolkar, A., Layward, L., Fezza, F., Bisogno, T., Di Marzo, V., 2001. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15, 300-302.
5. Benito, C., Romero, J.P., Tolon, R.M., Clemente, D., Docagne, F., Hillard, C.J., Guaza, C., Romero, J., 2007. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J. Neurosci. 27, 2396-2402. (Pubitemid 46340977)
6. Benito, C., Tolon, R.M., Pazos, M.R., Nunez, E., Castillo, A.I., Romero, J., 2008. Cannabinoid CB2 receptors in human brain inflammation. Br. J. Pharmacol. 153, 277-285.
7. Benveniste, E.N., 1997. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J. Mol. Med. 75, 165-173.
8. Berdyshev, E.V., 2000. Cannabinoid receptors and the regulation of immune response. Chem. Phys. Lipids 108, 169-190.
9. Billiards, S.S., Haynes, R.L., Folkerth, R.D., Trachtenberg, F.L., Liu, L.G., Volpe, J.J., Kinney, H.C., 2006. Development of microglia in the cerebral white matter of the human fetus and infant. J. Comp. Neurol. 497, 199-208.
10. Cabranes, A., Venderova, K., de Lago, E., Fezza, F., Sanchez, A., Mestre, L., Valenti, M., Garcia-Merino, A., Ramos, J.A., Di Marzo, V., Fernandez-Ruiz, J., 2005. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol. Dis. 20, 207-217.
11. Cabranes, A., Pryce, G., Baker, D., Fernandez-Ruiz, J., 2006. Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. Brain Res. 1107, 199-205. (Pubitemid 44205126)
12. Carlisle, S.J., Marciano-Cabral, F., Staab, A., Ludwick, C., Cabral, G.A., 2002. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int. Immunopharmacol. 2, 69-82.
13. Carrier, E.J., Kearn, C.S., Barkmeier, A.J., Breese, N.M., Yang, W., Nithipatikom, K., Pfister, S.L., Campbell, W.B., Hillard, C.J., 2004. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol. Pharmacol. 65, 999-1007.
14. Centonze, D., Bari, M., Rossi, S., Prosperetti, C., Furlan, R., Fezza, F., De Chiara, V., Battistini, L., Bernardi, G., Bernardini, S., Martino, G., Maccarrone, M., 2007a. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 130, 2543-2553. (Pubitemid 47511703)
15. Centonze, D., Finazzi-Agro, A., Bernardi, G., Maccarrone, M., 2007b. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol. Sci. 28, 180-187.
16. Colton, C.A., 2009. Heterogeneity of microglial activation in the innate immune response in the brain. J. Neuroimmune Pharmacol. 4, 399-418.
17. Consroe, P., 1998. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol. Dis. 5, 534-551.
18. De Petrocellis, L., Di Marzo, V., 2010. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J. Neuroimmune Pharmacol. 5, 103-121.
19. Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., Mechoulam, R., 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949. (Pubitemid 23026736)
20. Docagne, F., Muneton, V., Clemente, D., Ali, C., Loria, F., Correa, F., Hernangomez, M., Mestre, L., Vivien, D., Guaza, C., 2007. Excitotoxicity in a chronic model of multiple sclerosis: neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Mol. Cell. Neurosci. 34, 551-561.
21. Einstein, O., Grigoriadis, N., Mizrachi-Kol, R., Reinhartz, E., Polyzoidou, E., Lavon, I., Milonas, I., Karussis, D., Abramsky, O., Ben-Hur, T., 2006. Transplanted neural precursor cells reduce brain inflammation to attenuate chronic experimental autoimmune encephalomyelitis. Exp. Neurol. 198, 275-284.
22. Fleming, K.K., Bovaird, J.A., Mosier, M.C., Emerson, M.R., LeVine, S.M., Marquis, J.G., 2005. Statistical analysis of data from studies on experimental autoimmune encephalomyelitis. J. Neuroimmunol. 170, 71-84. (Pubitemid 41740908)
23. Franklin, A., Parmentier-Batteur, S., Walter, L., Greenberg, D.A., Stella, N., 2003. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J. Neurosci. 23, 7767-7775. (Pubitemid 37052344)
24. Gallily, R., Breuer, A., Mechoulam, R., 2000. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur. J. Pharmacol. 406, R5-R7.
25. Gong, J.P., Onaivi, E.S., Ishiguro, H., Liu, Q.R., Tagliaferro, P.A., Brusco, A., Uhl, G.R., 2006. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 1071, 10-23. (Pubitemid 43255471)
26. Gonsiorek, W., Lunn, C., Fan, X., Narula, S., Lundell, D., Hipkin, R.W., 2000. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol. Pharmacol. 57, 1045-1050.
27. Grigoriadis, N., Ben-Hur, T., Karussis, D., Milonas, I., 2004. Axonal damage in multiple sclerosis: a complex issue in a complex disease. Clin. Neurol. Neurosurg. 106, 211-217.
28. Grigoriadis, N., Grigoriadis, S., Polyzoidou, E., Milonas, I., Karussis, D., 2006. Neuroinflammation in multiple sclerosis: evidence for autoimmune dysregulation, not simple autoimmune reaction. Clin. Neurol. Neurosurg. 108, 241-244.
29. Grimsey, N.L., Goodfellow, C.E., Scotter, E.L., Dowie, M.J., Glass, M., Graham, E.S., 2008. Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal! J. Neurosci. Methods 171, 78-86.
30. Guzman, M., Sanchez, C., Galve-Roperh, I., 2001. Control of the cell survival/death decision by cannabinoids. J. Mol. Med. 78, 613-625.
31. Guzman, M., Sanchez, C., Galve-Roperh, I., 2002. Cannabinoids and cell fate. Pharmacol. Ther. 95, 175-184.
32. Hashimotodani, Y., Ohno-Shosaku, T., Kano, M., 2007. Presynaptic monoacylglycerol lipase activity determines basal endocannabinoid tone and terminates retrograde endocannabinoid signaling in the hippocampus. J. Neurosci. 27, 1211-1219. (Pubitemid 46203330)
33. Irony-Tur-Sinai, M., Grigoriadis, N., Lourbopoulos, A., Pinto-Maaravi, F., Abramsky, O., Brenner, T., 2006. Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein. Exp. Neurol. 198, 136-144.
34. Kaplan, B.L., Ouyang, Y., Rockwell, C.E., Rao, G.K., Kaminski, N.E., 2005. 2-Arachidonoyl-glycerol suppresses interferon-gamma production in phorbol ester/ionomycin-activated mouse splenocytes independent of CB1 or CB2. J. Leukoc. Biol. 77, 966-974.
35. Klein, T.W., Newton, C., Larsen, K., Lu, L., Perkins, I., Nong, L., Friedman, H., 2003. The cannabinoid system and immune modulation. J. Leukoc. Biol. 74, 486-496.
36. Kreutz, S., Koch, M., Bottger, C., Ghadban, C., Korf, H.W., Dehghani, F., 2009. 2-Arachidonoylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol-sensitive receptors on microglial cells. Glia 57, 286-294.
37. Lai, A.Y., Todd, K.G., 2008. Differential regulation of trophic and proinflammatory microglial effectors is dependent on severity of neuronal injury. Glia 56, 259-270.
38. Lee, M., Yang, K.H., Kaminski, N.E., 1995. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J. Pharmacol. Exp. Ther. 275, 529-536.
39. Lourbopoulos, A., Grigoriadis, S., Symeonidou, C., Deretzi, G., Taskos, N., Shohami, E., Grigoriadis, N., 2007. Modified Bielschowsky silver impregnation combined with Hematoxylin or Cresyl Violet counterstaining as a potential tool for the simultaneous study of inflammation and axonal injury in the central nervous system. Aristotle Univ. Med J. 34, 31-39.
40. Maresz, K., Pryce, G., Ponomarev, E.D., Marsicano, G., Croxford, J.L., Shriver, L.P., Ledent, C., Cheng, X., Carrier, E.J., Mann, M.K., Giovannoni, G., Pertwee, R.G., Yamamura, T., Buckley, N.E., Hillard, C.J., Lutz, B., Baker, D., Dittel, B.N., 2007. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med. 13, 492-497.
41. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., Bonner, T.I., 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564.
42. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N.E., Schatz, A.R., Gopher, A., Almog, S., Martin, B.R., Compton, D.R., et al., 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90.
43. Mechoulam, R., Panikashvili, D., Shohami, E., 2002. Cannabinoids and brain injury: therapeutic implications. Trends Mol. Med. 8, 58-61.
44. Mechoulam, R., Shohami, E., 2007. Endocannabinoids and traumatic brain injury. Mol. Neurobiol. 36, 68-74.
45. Munro, S., Thomas, K.L., Abu-Shaar, M., 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65. (Pubitemid 23305569)
46. Nagayama, T., Sinor, A.D., Simon, R.P., Chen, J., Graham, S.H., Jin, K., Greenberg, D.A., 1999. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19, 2987-2995. (Pubitemid 29173995)
47. Napoli, I., Neumann, H., 2010. Protective effects of microglia in multiple sclerosis. Exp. Neurol. 225, 24-28.
48. Neumann, H., 2003. Molecular mechanisms of axonal damage in inflammatory central nervous system diseases. Curr. Opin. Neurol. 16, 267-273.
49. Nguyen, K.B., Pender, M.P., 1998. Phagocytosis of apoptotic lymphocytes by oligodendrocytes in experimental autoimmune encephalomyelitis. Acta Neuropathol. 95, 40-46. (Pubitemid 28075925)
50. Okuda, Y., Apatoff, B.R., Posnett, D.N., 2006. Apoptosis of T cells in peripheral blood and cerebrospinal fluid is associated with disease activity of multiple sclerosis. J. Neuroimmunol. 171, 163-170. (Pubitemid 41832287)
51. Onaivi, E.S., Ishiguro, H., Gong, J.P., Patel, S., Perchuk, A., Meozzi, P.A., Myers, L., Mora, Z., Tagliaferro, P., Gardner, E., Brusco, A., Akinshola, B.E., Liu, Q.R., Hope, B., Iwasaki, S., Arinami, T., Teasenfitz, L., Uhl, G.R., 2006. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann. NY Acad. Sci. 1074, 514-536.
52. Ouyang, Y., Hwang, S.G., Han, S.H., Kaminski, N.E., 1998. Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells. Mol. Pharmacol. 53, 676-683.
53. Pandey, R., Mousawy, K., Nagarkatti, M., Nagarkatti, P., 2009. Endocannabinoids and immune regulation. Pharmacol. Res. 60, 85-92.
54. Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanus, L., Breuer, A., Mechoulam, R., Shohami, E., 2001. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527-531. (Pubitemid 32938751)
55. Panikashvili, D., Mechoulam, R., Beni, S.M., Alexandrovich, A., Shohami, E., 2005. CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J. Cereb. Blood Flow Metab. 25, 477-484.
56. Pender, M.P., Rist, M.J., 2001. Apoptosis of inflammatory cells in immune control of the nervous system: role of glia. Glia 36, 137-144. (Pubitemid 33055902)
57. Pender, M.P., 2007. Treating autoimmune demyelination by augmenting lymphocyte apoptosis in the central nervous system. J. Neuroimmunol. 191, 26-38. (Pubitemid 350060996)
58. Pertwee, R.G., 2009. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 156, 397-411.
59. Pertwee, R.G., 2010. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem. 17, 1360-1381.
60. Pryce, G., Baker, D., 2007. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br. J. Pharmacol. 150, 519-525.
61. Rockwell, C.E., Snider, N.T., Thompson, J.T., Vanden Heuvel, J.P., Kaminski, N.E., 2006. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol. Pharmacol. 70, 101-111.
62. Sagredo, O., Garcia-Arencibia, M., de Lago, E., Finetti, S., Decio, A., Fernandez-Ruiz, J., 2007. Cannabinoids and neuroprotection in basal ganglia disorders. Mol. Neurobiol. 36, 82-91.
63. Sanchez, A.J., Gonzalez-Perez, P., Galve-Roperh, I., Garcia-Merino, A., 2006. R-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor. Biochem. Pharmacol. 72, 1697-1706.
64. Schilling, T., Lehmann, F., Ruckert, B., Eder, C., 2004. Physiological mechanisms of lysophosphatidylcholine-induced de-ramification of murine microglia. J. Physiol. 557, 105-120. (Pubitemid 38771640)
65. Schmied, M., Breitschopf, H., Gold, R., Zischler, H., Rothe, G., Wekerle, H., Lassmann, H., 1993. Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am. J. Pathol. 143, 446-452.
66. Shohami, E., Mechoulam, R., 2006. Multiple sclerosis may disrupt endocannabinoid brain protection mechanism. Proc. Natl Acad. Sci. U.S.A. 103, 6087-6088.
67. Smith, M.E., 2001. Phagocytic properties of microglia in vitro: implications for a role in multiple sclerosis and EAE. Microsc. Res. Tech. 54, 81-94.
68. Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., Waku, K., 1995. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89-97.
69. Sugiura, T., Kondo, S., Kishimoto, S., Miyashita, T., Nakane, S., Kodaka, T., Suhara, Y., Takayama, H., Waku, K., 2000. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem. 275, 605-612.
70. Sugiura, T., Oka, S., Gokoh, M., Kishimoto, S., Waku, K., 2004. New perspectives in the studies on endocannabinoid and cannabis: 2-arachidonoylglycerol as a possible novel mediator of inflammation. J. Pharmacol. Sci. 96, 367-375.
71. Sunnemark, D., Eltayeb, S., Wallstrom, E., Appelsved, L., Malmberg, A., Lassmann, H., Ericsson-Dahlstrand, A., Piehl, F., Olsson, T., 2003. Differential expression of the chemokine receptors CX3CR1 and CCR1 by microglia and macrophages in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis. Brain Pathol. 13, 617-629. (Pubitemid 37420704)
72. Trapp, B.D., Bo, L., Mork, S., Chang, A., 1999. Pathogenesis of tissue injury in MS lesions. J. Neuroimmunol. 98, 49-56. (Pubitemid 29295407)
73. Van Sickle, M.D., Duncan, M., Kingsley, P.J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J.S., Marnett, L.J., Di Marzo, V., Pittman, Q.J., Patel, K.D., Sharkey, K.A., 2005. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310, 329-332. (Pubitemid 41457202)
74. Wallace, M.J., Blair, R.E., Falenski, K.W., Martin, B.R., DeLorenzo, R.J., 2003. The endogenous cannabinoid systemregulates seizure frequency and duration in a model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 307, 129-137.
75. Wilms, H., Hartmann, D., Sievers, J., 1997. Ramification of microglia, monocytes and macrophages in vitro: influences of various epithelial and mesenchymal cells and their conditioned media. Cell Tissue Res. 287, 447-458. (Pubitemid 27113126)
76. Witting, A., Walter, L., Wacker, J., Moller, T., Stella, N., 2004a. P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. Proc. Natl Acad. Sci. U.S.A. 101, 3214-3219.
77. Witting, A., Weydt, P., Hong, S., Kliot, M., Moller, T., Stella, N., 2004b. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J. Neurochem. 89, 1555-1557. (Pubitemid 38802677)
78. Witting, A., Chen, L., Cudaback, E., Straiker, A., Walter, L., Rickman, B., Moller, T., Brosnan, C., Stella, N., 2006. Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. Proc. Natl Acad. Sci. U.S.A. 103, 6362-6367.
79. Wujek, J.R., Bjartmar, C., Richer, E., Ransohoff, R.M., Yu, M., Tuohy, V.K., Trapp, B.D., 2002. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J. Neuropathol. Exp. Neurol. 61, 23-32.